miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2021.06.005

癌变·畸变·突变 ›› 2021, Vol. 33 ›› Issue (6): 430-434.doi: 10.3969/j.issn.1004-616x.2021.06.005

miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义

焦文鹏¹, 侯琳¹, 崔妹娟², 焦文静¹, 马鸣¹, 张金艳¹

1. 河北医科大学第四医院, 河北石家庄 050011;
2. 河北医科大学第三医院, 河北石家庄 050051

收稿日期:2020-11-24 修回日期:2021-09-01 出版日期:2021-11-30 发布日期:2021-12-04
通讯作者: 张金艳,E-mail:jinyanzhang66@163.com E-mail:jinyanzhang66@163.com
作者简介:焦文鹏,E-mail:jiaowenpeng163@163.com。
基金资助:
河北省卫健委基金（20200110）

Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance

JIAO Wenpeng¹, HOU Lin¹, CUI Meijuan², JIAO Wenjing¹, MA Ming¹, ZHANG Jinyan¹

1. The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
2. The Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei, China

Received:2020-11-24 Revised:2021-09-01 Online:2021-11-30 Published:2021-12-04

摘要/Abstract

摘要： 目的： 探讨miR-93-5p和miR-106b-5p在酒精性肝硬化肝癌（酒精相关性肝癌）患者中的表达水平及其临床意义。方法： 选取酒精相关性肝癌患者穿刺组织蜡块10例，根据性别、年龄配对原则选取10例酒精性肝硬化患者穿刺组织蜡块，采用实时荧光定量PCR（qPCR）检测组织中的miR-93-5p和miR-106b-5p表达水平。另收集河北医科大学第四医院2014年1月1日—2016年12月31日住院治疗的酒精相关性肝癌患者资料71例，治疗前抽取患者外周血，qPCR法检测血清中miR-93-5p和miR-106b-5p的表达水平，分析miR-93-5p和miR-106b-5p表达水平与患者临床病理指标和预后的关系。结果： 酒精相关性肝癌患者癌组织中miR-93-5p和miR-106b-5p的表达水平显著高于酒精性肝硬化患者（均P<0.01）。miR-93-5p或miR-106b-5p高表达组肿瘤最大径较低表达组显著增加（P<0.01），且临床分期较晚（P<0.01）。全组患者中，年龄<60岁组患者生存率显著优于≥60岁组患者（P=0.03）；肿瘤最大径<5 cm组患者生存率显著优于≥5 cm组患者（P=0.01）；TNM分期Ⅰ+Ⅱ期患者生存率高于Ⅲ期患者（P=0.02）；miR-93-5p或miR-106b-5p高表达组患者生存率较低表达组患者显著降低（P≤0.01）；年龄和miR-106b-5p表达水平是患者预后的独立影响因素（P值分别为0.02和0.03）。结论： miR-93-5p和miR-106b-5p有作为酒精相关性肝癌肿瘤标志物的潜力，治疗前检测其表达水平可以预测患者临床病理指标和预后。

Abstract: OBJECTIVE: Alcohol-related liver cancer has become a common type of liver cancer. Our aim was to identify tumor markers which could be used to screen patients with early liver cancer from patients with alcoholic cirrhosis and to improve the prognosis of patients,especially in expression levels of miR-93-5p and miR-106b-5p. METHODS: Randomly selected 10 patients with alcoholic liver cirrhosis in the pathology department of our hospital,and alcoholic cirrhosis/liver cancer tissue wax blocks from 10 patients according to gender and age matching. Expression levels of miR-93-5p and miR-106b-5p in the tissue wax blocks were determined. In addition,71 patients with alcoholic liver cirrhosis and liver cancer who were hospitalized in our hospital from January 1,2014 to December 31,2016 were recruited. Serum samples were collected from these patients before treatment and expression levels of miR-93-5p and miR-106b-5p were detected. Relationships between expression levels of miR-93-5p and miR-106b-5p and clinicopathological characteristics and prognosis of patients were analyzed. RESULTS: Expression levels of miR-93-5p and miR-106b-5p in cancer tissues were significantly higher than those from patients with alcoholic liver cirrhosis(all P<0.01). The maximum diameters for tumors in the high miR-93-5p group were lower and the miR-93-5p group was significantly enlarged (P<0.01),and the clinical stage was later (P<0.01). The high miR-106b-5p group had significantly greater tumor maximum diameter than miR-106b-5p group (P<0.01),and the clinical stage of the high miR-106b-5p group was later (P<0.01). In the entire group of patients,the survival rates of patients in the age <60 years were significantly better than that in the ≥ 60 years group (P=0.03). Survival rates of patients in the <5cm tumor diameter group were significantly better than that in the ≥ 5 cm group (P=0.01). Survival rates of patients in the group Ⅰ+Ⅱ were higher than that in group Ⅲ (P=0.02). Survival rates of patients in the high miR-93-5p group was significantly lower than that of the patients in the miR-93-5p group (P=0.01). Survival rates of patients in the high miR-106b-5p group were significantly lower than that in the low miR-106b-5p group (P<0.01). Age and miR-106b-5p expression levels were independent factors affecting prognosis of the patients (P=0.02;P=0.03). CONCLUSION: miR-93-5p and miR-106b-5p showed potential to be tumor markers for alcohol-related liver cancers. Detection of their expression levels before treatment was predictive of pathological characteristics and prognosis of the patients.

Key words: alcohol-related liver cancer, miR-93-5p, miR-106b-5p, clinical stage, prognosis

中图分类号:

R735.7

焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.

JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.

参考文献

[1] WEI K R, YU X, ZHENG R S, et al. Incidence and mortality of liver cancer in China, 2010[J]. Chin J Cancer, 2014, 33(8):388-394.
[2] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[3] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:Cancer J Clin, 2018, 68(6):394-424.
[4] WANG J W, QIAN Y, WU C S, et al. Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma[J]. Int J Med Sci, 2020, 17(18):3190-3199.
[5] 徐佰国, 向慧玲, 韩涛. 慢性乙型肝炎患者抗病毒治疗过程中发生肝癌的风险预测模型[J]. 临床肝胆病杂志, 2021, 37(2):433-436.
[6] 刘昊天, 陈康, 邓柱鉴, 等. 术前乙型肝炎病毒DNA载量对肝细胞癌患者肝切除术后预后的影响[J]. 中华肝胆外科杂志, 2021, 27(6):429-433.
[7] 何倩玉, 李俊峰, 毛小荣. 慢性HBV感染相关性肝癌发生的突变基因研究[J]. 肝脏, 2021, 26(7):811-814.
[8] 丁梦梦, 高沿航. IL-17信号通路在酒精相关性肝癌发生、发展中的作用[J]. 肝脏, 2020, 25(6):562-564.
[9] PIMPIN L, CORTEZ-PINTO H, NEGRO F, et al. Burden of liver disease in Europe:Epidemiology and analysis of risk factors to identify prevention policies[J]. J Hepatol, 2018, 69(3):718-735.
[10] 张玉元, 李臻, 詹鹏超, 等.肝癌标志物研究进展[J].国际肿瘤学杂志, 2021, 48(4):241-245.
[11] FAN X M, CHEN W, FU Z Y, et al. microRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells[J]. Oncol Lett, 2017, 14(5):5069-5076.
[12] PANG K C, STEPHEN S, DINGER M E, et al. RNAdb 2.0:an expanded database of mammalian non-coding RNAs[J]. Nucleic Acids Res, 2007, 35:178-182.
[13] ZHANG X, XU X Y, GE G H, et al. miR-498 inhibits the growth and metastasis of liver cancer by targeting ZEB2[J]. Oncol Rep, 2019, 41(3):1638-1648.
[14] LI B, LIU D, YANG P H, et al. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway[J]. Gene, 2019, 707:78-85.
[15] RAN R Z, CHEN J, CUI L J, et al. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway[J]. Exp Cell Res, 2019, 378(1):66-75.
[16] SUN X Y, HAN X M, ZHAO X L, et al. MiR-93-5p promotes cervical cancer progression by targeting THBS₂/MMPS signal pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(12):5113-5121.
[17] WU H, LIU L, ZHU J M. miR-93-5p inhibited proliferation and metastasis of glioma cells by targeting MMP2[J]. Eur Rev Med Pharmacol Sci, 2019, 23(21):9517-9524.
[18] GU H, GU S S, ZHANG X L, et al. miR-106b-5p promotes aggressive progression of hepatocellular carcinoma via targeting RUNX3[J]. Cancer Med, 2019, 8(15):6756-6767.
[19] WEI K, PAN C F, YAO G L, et al. miR-106b-5p promotes proliferation and inhibits apoptosis by regulating BTG3 in non-small cell lung cancer[J]. Cell Physiol Biochem, 2017, 44(4):1545-1558.

miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义

Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛松, 胡加海, 董祥宁. PGAM5在胰腺癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2024, 36(1): 29-34.
[2]	王科芳, 陈瑜, 吴陈雨, 刘梅, 汪丽杰, 田建广, 周小会, 许岚. 白细胞介素-17A与雌激素受体α和β在上皮性卵巢癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2024, 36(1): 42-47.
[3]	朱文标, 丘波, 谢寿城, 肖焕钦, 刘高敏. 跨膜蛋白79在肝细胞癌中的表达及临床意义[J]. 癌变·畸变·突变, 2023, 35(6): 426-430.
[4]	许金花, 李静静, 吴国峰, 任亚俊, 王雪, 张骞云. 非小细胞肺癌患者血清miR-146a与TNF-α、Treg的相关性及其对预后判断的价值[J]. 癌变·畸变·突变, 2023, 35(6): 462-466.
[5]	杨上英, 黄明翔, 许德新, 刘加夫, 陈新富. DNAJB4与非小细胞肺癌免疫细胞浸润和患者预后的相关性分析[J]. 癌变·畸变·突变, 2023, 35(6): 467-472.
[6]	高榴, 禹莉. 线粒体转录因子A在肿瘤发生发展中作用的研究进展[J]. 癌变·畸变·突变, 2023, 35(6): 485-488.
[7]	呙文静, 邓慧, 宋萍, 张孟贤. 转化生长因子β诱导蛋白在胶质瘤中的表达及生物学功能[J]. 癌变·畸变·突变, 2023, 35(5): 341-348.
[8]	韦来凤, 洪超群, 陈柳伊, 许镒洧, 伍方财. 实验室炎症相关指标的列线图对预测舌鳞状细胞癌患者手术预后的价值[J]. 癌变·畸变·突变, 2023, 35(5): 366-373.
[9]	杨程晴, 崔永辉, 郑紫恒. 结肠癌患者血清中miR-653-5p的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(4): 261-265.
[10]	刘瑞雪, 张力为. 腺苷酸活化蛋白激酶在哈萨克族食管鳞癌组织中的表达及意义[J]. 癌变·畸变·突变, 2023, 35(4): 285-291.
[11]	刘颖, 王蕊, 郭晓, 董律吏, 张艳, 赵银环, 杜芸. 肺腺癌胸腔积液DNA倍体异常与EGFR突变的关系及其对患者预后的影响[J]. 癌变·畸变·突变, 2023, 35(3): 178-182,186.
[12]	王平, 王华勇, 王浩, 雷大军. 骨肉瘤患者血清外泌体中miR-193a和miR-21-5p表达水平及其临床意义[J]. 癌变·畸变·突变, 2023, 35(3): 197-201.
[13]	黄利丹, 吴月明, 王亚帝, 谭琦. EGFR突变型肺腺癌组织中VEGF-A蛋白的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(2): 116-120.
[14]	谭健华, 赖姚圳, 唐丽华, 周莉. 2种不同疗法对晚期上皮性卵巢癌的疗效及患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(2): 131-138.
[15]	秦景娜, 周英发, 刘贺勇. 炎症指标和肿瘤标记物联合检测对术前胃癌分期的诊断价值[J]. 癌变·畸变·突变, 2023, 35(2): 139-143.